pharma · Ph+ ALL · Unresectable or Metastatic Melanoma or Advanced Solid Tumors
Ascentage Pharma
Ascentage Pharma Group
Ascentage Pharma Group is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ph+ ALL, Unresectable or Metastatic Melanoma or Advanced Solid Tumors. NovaPharmaNews links 2 clinical program(
USA HQ
2009 Founded
178 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- USA
- Founded
- 2009
- Employees
- 178
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Phase 1b: APG-115+pembrolizumab
Phase 2 · small molecule · Unresectable or Metastatic Melanoma or Advanced Solid Tumors
Phase 1b: APG-115+pembrolizumab for Unresectable or Metastatic Melanoma or Advanced Solid Tumors is a Phase 2 program (small_molecule) at Ascentage Pharma Group with 1 ClinicalTrials.gov record(s).
Internal code APG-115-US-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ascentage Pharma Group
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors
- Status
- active
- Trials
- 1